Neural Noise- Minimally invasive extra-epidural electrode implantation enables pain neuromodulation with reduced surgical risk.1
- The approach reduces barriers to neuromodulation adoption for chronic pain management.1 1
Weekly enrichment (2026-07-20)
- The referenced method, “SNAP” (Safe Neuromodulation Against Pain), places electrodes entirely outside the epidural space, clamped onto the vertebral arch (lamina) so the epidural space and protective ligamentum flavum remain intact.2
- The implant is a standalone unit consisting of two small metal “clip” electrodes on the dorsal (safe) side connected by a wire, a design intended to lower lead-migration risk.2
- This is a conceptual, in-silico feasibility study using finite-element modeling of the stimulation field, not a clinical trial.2
- Its rationale is to extend spinal cord stimulation to patients ineligible for standard epidural SCS, particularly those on chronic anticoagulant therapy.2
- The authors specifically target elderly patients, in whom both chronic pain and long-term anticoagulant use are highly prevalent.2
- Clinical efficacy in patients is not reported; the work is a design/simulation proof-of-concept pending further validation.2
- For context, other minimally invasive SCS advances use tubular-retractor midline paddle-lead placement, with one case series reporting an average blood loss of about 22.7 mL and reduced muscle dissection versus open laminectomy.3
- For context, a unilateral biportal endoscopic SCS series of 14 patients reported 92.8% (13/14) proceeding to permanent implantation, a mean endoscopic time of 76.3 ± 22.3 minutes, and no lead migration among implanted patients.4
- Neuromodulation implication: less-invasive lead placement could broaden neuromodulation eligibility and reduce surgical risk, though the SNAP approach specifically remains preclinical.2